Comparison of antibody responses following natural infection with Severe Acute Respiratory Syndrome Coronavirus 2 or receipt of CoronaVac or ChAdOx1 (AZD1222) vaccination in Chiang Mai, Thailand

BACKGROUND: In Thailand, early vaccination initiatives for SARS-CoV-2 relied on CoronaVac (Sinovac Life Sciences) and ChAdOx1 (Oxford–AstraZeneca) vaccines. However, the data of immunogenicity of these two vaccines in Thai populations is limited. This real time, head-to-head comparative study was co...

Descripción completa

Detalles Bibliográficos
Autores principales: Hongjaisee, Sayamon, Chawansuntati, Kriangkrai, Sripan, Patumrat, Rattanathammethee, Kritsadee, Sakkhachornphop, Supachai, Chaiwarith, Romanee, Sudjaritruk, Tavitiya, Supparatpinyo, Khuanchai, Wipasa, Jiraprapa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Regular paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119672/
https://www.ncbi.nlm.nih.gov/pubmed/37155476
http://dx.doi.org/10.1016/j.jvacx.2023.100305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119672/
https://www.ncbi.nlm.nih.gov/pubmed/37155476
http://dx.doi.org/10.1016/j.jvacx.2023.100305

Ejemplares similares